Navigation Links
CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
Date:6/16/2009

ology/pharmaceutical companies and academic research institutions. The use of a cold +4 degrees Celsius aseptic fill, as opposed to the room temperature fill usually employed for these and other products, significantly increases the probability of maintaining the biological activity and potency of these drugs, and thus potentially extending the drugs' shelf-life. When launched, CEL-SCI will be the only company providing this "true cold" +4 degrees Celsius filling service on a contractual basis to other companies and academic institutions. CEL-SCI will also be able to offer normal room temperature fills at the same facility.

Dr. Talor said, "Many of the large pharmaceutical and generic companies are getting ready for new biosimilar legislation in the US. They have invested a great deal of effort and money in this area. However, as best we know, none have "true cold" fill capability that will allow them to bring these drugs to market faster, while saving substantial cost. We believe that we will be in an excellent position to work with them to meet their growing needs as they will try to rush new drugs to market."

CEL-SCI's unique, cold aseptic filling suite can be operated at temperatures between 2 degrees Celsius and room temperatures, including humidity control. The Fill/Finish Facility and the aseptic filling suites have all been designed to meet both FDA and EU ISO classifications. CEL-SCI also has additional capability to formulate, inspect, label and package these products at cold temperatures.

Background on CEL-SCI's "true cold" +4 degrees Celsius Fill/Finish facility:

The fastest area of growth in the Biopharmaceutical and Pharmaceutical market is the area of biologics, most recently the area of stem cell derived products, and in the future biosimilars (copies of biologics). These compounds and therapies are derived from or mimic human cells or proteins and other molecules
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
3. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
4. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
5. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
6. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
7. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
10. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
11. Scientists advance safety of nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... If proposed health care legislation is enacted, it ... system. Approximately 18.4 million Californians and 161 million ... employer-based insurance for their health care coverage. ... legislation entail specific requirements for employer-based insurance. ... firms that currently comply with most new standards, ...
(Date:12/16/2009)... Raises Significant Funds to Benefit of Children with Autism ... Taylor, Gary Cole and Zachary Levi Join Ben Stiller ... ANGELES, Dec. 16 At its 13th annual ... individuals. Hasbro President & CEO Brian ... in recognition of his far-reaching philanthropic leadership and commitment ...
(Date:12/16/2009)... -- Immucor, Inc. (Nasdaq: BLUD ), a global ... transfusion industry, today announced that Paul D. Mintz, M.D. ... independent director, effective January 1, 2010. ,, Dr. ... medicine for more than 30 years. He is a ... of Virginia School of Medicine. He also serves as ...
(Date:12/16/2009)... The most widely used human embryonic stem cell ... justice questions that must be addressed to ensure that ... according to a University of Michigan research team. ,, ... U-M team analyzed 47 embryonic stem cell lines, including ... researchers. The scientists determined the genetic ancestry of each ...
(Date:12/16/2009)... Scientists pinpoint seven that increase susceptibility to disease ... genes associated with increased susceptibility to leprosy have ... , The researchers, who analyzed more than 10,000 ... in China, said their discovery highlights the important ... the development of leprosy. , "Though leprosy is ...
Breaking Medicine News(10 mins):Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:Immucor Appoints New Board Director 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:Leprosy Genes Identified 2
... by Avalere Health found that nearly 30% of long-term ... higher than amounts reported in widely used previous estimates. ... assisted living, a key component of long-term care.This analysis, ... that individuals and their families contributed an estimated $64 ...
... Bio-Optronics, Inc., a leader in healthcare workflow ... solution, the only comprehensive, flexible, and easy-to-use patient ... capability.The Joint Commission,s #1 patient safety goal is ... ID bands are difficult to read and time-consuming ...
... Philadelphia, 5 March 2009 The new medical subspecialty ... the way in providing technically advanced yet cost-effective care ... in the March issue of the Journal of ... the Heart Failure Society of America (HFSA) and the ...
... Connecticut,s Largest Home Care Agencies Automates and Connects ... 5 Allscripts announced today that VNA HealthCare, ... Homecare as its electronic home care system. VNA ... independent living services to 60 communities in the ...
... only specialized clinic furthers AED industry-leading commitment to ... 67th annual meeting of the American Academy of ... Inc. (Nasdaq: SLTM ) today announced ... to advance the company,s new product development, facilitate ...
... United States and Canadian Academy of Pathology (USCAP)SUNNYVALE, ... the Elekta Group and leading provider of software ... the introduction of PowerPath version 9.3, including new ... at USCAP conference in Boston, March 9-11, 2009. ...
Other Medicine News:Health News:Almost 30% of Long-Term Care is Financed Out-of-Pocket, Report Finds 2Health News:bioPoint(TM) PID Wristband Software Improves Patient Identification Accuracy and Safety 2Health News:New specialty to focus on advanced heart failure and heart transplantation 2Health News:VNA HealthCare Selects Allscripts Homecare 2Health News:VNA HealthCare Selects Allscripts Homecare 3Health News:VNA HealthCare Selects Allscripts Homecare 4Health News:VNA HealthCare Selects Allscripts Homecare 5Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 3Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 2Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 3
(Date:12/16/2009)... N.J., Dec. 16 Ethicon, Inc., a ... company and a worldwide leader in surgical care, ... company dedicated to designing, developing and commercializing devices ... throat (ENT), today announced a definitive merger agreement ... transaction for approximately $785 million net of estimated ...
(Date:12/16/2009)... LAKE FOREST, Ill., Dec. 16 Hospira, Inc. ... pharmaceutical and medication delivery company, today announced that it ... and full-year 2009 results and projections for 2010 on ... ,, The company will release its fourth-quarter and full-year ... market open and the conference call. ,, A live ...
(Date:12/16/2009)... 16 International, well-known,scientific experts ... GFT505 (80 mg/day),data presented as "extremely ... scientists and clinicians critically reviewed these ... of generic lipid-modifying,treatments, fenofibrate and bezafibrate, ... observed in patients with metabolic syndrome,and ...
Breaking Medicine Technology:Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 1Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 2American Lung Association in Florida Joins Anti Recession Campaign by Forming Strategic Alliance With www i am anti recession com 54664 1American Lung Association in Florida Joins Anti Recession Campaign by Forming Strategic Alliance With www i am anti recession com 54664 2Study shows how to boost value of Alzheimers fighting compounds 54660 1Study shows how to boost value of Alzheimers fighting compounds 54660 2
... University graduate student has found a correlation between childhood obesity ... doctoral student in human nutrition, Manhattan, conducted research that found that ... of physical activity had greater amounts of airway narrowing after exercise. ... and inactive are having -- even at the age of 8 ...
... LONDON, Dec. 11 On December 11, 2008, ... and Drug Administration (FDA) - including the Drug ... Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee ... risks of asthma medications containing long-acting beta-agonists (LABAs). ...
Other Medicine Technology:K-State Researcher Finds Correlation Between Childhood Obesity and Asthma 2K-State Researcher Finds Correlation Between Childhood Obesity and Asthma 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 2AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 4
... Liquichek™ Reticulocyte Stain is ... stain for use in manual ... liquid product has a one ... at 230C and can be ...
Seroconversion and Antigen Panel Chart...
... CT/GC Controls are liquid controls ... of test procedures that detect ... Since they are specimen specific, ... either urine or endocervical/urethral swabs ...
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: